Recombinant lipoproteins reinforce cytotoxicity of doxorubicin to hepatocellular carcinoma

Journal of Drug Targeting

Volumn 22, Issue 1, 2014, Pages 76-85

  Wang, Baolong ^a   Yuan, Yuan ^a   Han, Lei ^a   Ye, Li ^a   Shi, Xunlong ^a   Feng, Meiqing ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

ApolipoproteinA I; Doxorubicin; Hepatocellular carcinoma; Recombined high density lipoprotein

Indexed keywords

DOXORUBICIN; HIGH DENSITY LIPOPROTEIN; NANOCARRIER;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG STABILITY; GENETIC RECOMBINATION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; PRIORITY JOURNAL; TISSUE DISTRIBUTION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL SURVIVAL; DOXORUBICIN; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HEP G2 CELLS; HUMANS; LIPOPROTEINS, HDL; LIVER NEOPLASMS; RECOMBINANT PROTEINS; TISSUE DISTRIBUTION;

EID: 84890422372     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2013.839687     Document Type: Article

References (41)

1. Paus R, Haslam IS, Sharov AA, Botchkarev VA. Pathobiology of chemotherapy-induced hair loss. Lancet Oncol 2013;14:e50-9.
2. Prata Kde L, Orellana MD, De Santis GC, et al. Effects of highdose chemotherapy on bone marrow multipotent mesenchymal stromal cells isolated from lymphoma patients. Exp Hematol 2010; 38:292-300 e4.
3. Cho K, Wang X, Nie S, et al. Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res: J Am Assoc Cancer Res 2008; 14:1310-16.
4. Malam Y, Loizidou M, Seifalian AM. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharmacol Sci 2009;30:592-9.
5. Takashi T, Mikihiko N, Akihiro T. Molecular targeting therapy of cancer drug resistance, apoptosis and survival signal. Cancer Sci 2002;94:15-21.
6. Farokhzad OC, Langer R. Impact of nanotechnology on drug delivery. ACS Nano 2009;3:16-20.
7. Brigger I, Dubernet C, Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev 2012;64:24-36.
8. Talekar M, Kendall J, Denny W, Garg S. Targeting of nanoparticles in cancer: drug delivery and diagnostics. Anti-Cancer Drugs 2011; 22:949-62.
9. Larsen AK, Escargueil AE, Skladanowski A. Resistance mechanisms associated with altered intracellular distribution of anticancer agents. Pharmacol Therapeut 2000;85:217-29.
10. Khlebtsov N, Dykman L. Biodistribution and toxicity of engineered gold nanoparticles: a review of in vitro and in vivo studies. Chem Soc Rev 2011;40:1647-71.
11. Yang Z, Liu Z, Allaker R, et al. A review of nanoparticle functionality and toxicity on the central nervous system. J Roy Soc Interface 2010;7:S411-22.
12. Kuznetsova NR, Sevrin C, Lespineux D, et al. Hemocompatibility of liposomes loaded with lipophilic prodrugs of methotrexate and melphalan in the lipid bilayer. J Control Rel: J Control Rel Soc 2012;160:394-400.
13. Ding Y, Wang W, Feng M, et al. A biomimetic nanovectormediated targeted cholesterol-conjugated siRNA delivery for tumor gene therapy. Biomaterials 2012;33:8893-905.
14. Shahzad MM, Mangala LS, Han HD, et al. Targeted delivery of small interfering RNA using reconstituted high-density lipoprotein nanoparticles. Neoplasia (New York, NY) 2011;13:309-19.
15. Rensen PC, de Vrueh RL, Kuiper J, et al. Recombinant lipoproteins: lipoprotein-like lipid particles for drug targeting. Adv Drug Deliv Rev 2001;47:251-76.
16. Rui M, Tang H, Li Y, et al. Recombinant high density lipoprotein nanoparticles for target-specific delivery of siRNA. Pharmaceut Res 2013;30:1203-14.
17. Rothblat GH, Phillips MC. High-density lipoprotein heterogeneity and function in reverse cholesterol transport. Curr Opin Lipid 2010; 21:229-38.
18. Cao WM, Murao K, Imachi H, et al. A mutant high-density lipoprotein receptor inhibits proliferation of human breast cancer cells. Cancer Res 2004;64:1515-21.
19. Ishida T, Kiwada H. Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes. Int J Pharmaceut 2008;354:56-62.
20. Cormode DP, Frias JC, Ma Y, et al. HDL as a contrast agent for medical imaging. Clin Lipid 2009;4:493-500.
21. Yuan Y, Wang W, Wang B, et al. Delivery of hydrophilic drug doxorubicin hydrochloride-targeted liver using apoAI as carrier. J Drug Target 2013;21:367-74.
22. Feng M-q, Cai Q-s, Song D-x, et al. High yield and secretion of recombinant human apolipoprotein AI in Pichia pastoris. Prot Exp Purif 2006;46:337-42.
23. Dong X, Mattingly CA, Tseng MT, et al. Doxorubicin and paclitaxel-loaded lipid-based nanoparticles overcome multidrug resistance by inhibiting P-glycoprotein and depleting ATP. Cancer Res 2009;69:3918-26.
24. Chen Z, Deng J, Zhao Y, Tao T. Cyclic RGD peptide-modified liposomal drug delivery system: enhanced cellular uptake in vitro and improved pharmacokinetics in rats. Int J Nanomed 2012;7: 3803-11.
25. Pradhan P, Banerjee R, Bahadur D, et al. Targeted magnetic liposomes loaded with doxorubicin. Liposomes: Springer; 2010:279-93.
26. Park J, Fong PM, Lu J, et al. PEGylated PLGA nanoparticles for the improved delivery of doxorubicin. Nanomed: Nanotechnol Biol Med 2009;5:410-18.
27. Kopecka J, Campia I, Olivero P, et al. A LDL-masked liposomaldoxorubicin reverses drug resistance in human cancer cells. J Control Rel: J Control Rel Soc 2011;149:196-205.
28. Lou B, Liao X-L, Wu M-P, et al. High-density lipoprotein as a potential carrier for delivery of a lipophilic antitumoral drug into hepatoma cells. World J Gastroenterol 2005;11:954-9.
29. Su F, Kozak KR, Imaizumi S, et al. Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides inhibit tumor development in a mouse model of ovarian cancer. Proc Natl Acad Sci USA 2010;107: 19997-20002.
30. Gao F, Vasquez SX, Su F, et al. L-5F, an apolipoprotein A-I mimetic, inhibits tumor angiogenesis by suppressing VEGF/basic FGF signaling pathways. Integr Biol: Quant Biosci Nano Macro 2011;3:479-89.
31. Ganapathy E, Su F, Meriwether D, et al. D-4F, an apoA-I mimetic peptide, inhibits proliferation and tumorigenicity of epithelial ovarian cancer cells by upregulating the antioxidant enzyme MnSOD. Int J Cancer 2012;130:1071-81.
32. Ganz W, Sridhar K, Ganz S, et al. Review of tests for monitoring doxorubicin-lnduced cardiomyopathy. Oncology 2009;53:461-70.
33. Bird BRH, Swain SM. Cardiac toxicity in breast cancer survivors: review of potential cardiac problems. Clin Cancer Res 2008;14: 14-24.
34. Mohan P, Rapoport N. Doxorubicin as a molecular nanotheranostic agent: effect of doxorubicin encapsulation in micelles or nanoemulsions on the ultrasound-mediated intracellular delivery and nuclear trafficking. Mol Pharmaceut 2010;7:1959-73.
35. Goldberg MS. siRNA delivery for the treatment of ovarian cancer. Methods 2013. doi: 10.1016/j.ymeth.2013.01.007.
36. Fotakis G, Timbrell JA. In vitro cytotoxicity assays: comparison of LDH, neutral red, MTT and protein assay in hepatoma cell lines following exposure to cadmium chloride. Toxicol Lett 2006;160: 171-7.
37. Ziegler U, Groscurth P. Morphological features of cell death. Physiology 2004;19:124-8.
38. Wang S, Konorev EA, Kotamraju S, et al. Doxorubicin induces apoptosis in normal and tumor cells via distinctly different mechanisms. intermediacy of H(2)O(2)-and p53-dependent pathways. J Biol Chem 2004;279:25535-43.
39. Liu X, Suo R, Xiong SL, et al. HDL drug carriers for targeted therapy. Clin Chim Acta; Int J Clin Chem 2013;415:94-100.
40. Sabnis N, Nair M, Israel M, et al. Enhanced solubility and functionality of valrubicin (AD-32) against cancer cells upon encapsulation into biocompatible nanoparticles. Int J Nanomedicine 2012;7:975-83.
41. Feng M, Cai Q, Huang H, Zhou P. Liver targeting and anti-HBV activity of reconstituted HDL-acyclovir palmitate complex. Eur J Pharmaceut Biopharmaceut 2008;68:688-93.